Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INO-4500 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| INO-4500 Group A | EXPERIMENTAL | Participants will receive 1 ID injection of 1 mg/dose INO-4500 followed by EP using the CELLECTRA™ 2000 device. |
| INO-4500 Group B | EXPERIMENTAL | Participants will receive 2 ID injections of 1 mg/dose INO-4500 followed by EP using the CELLECTRA™ 2000 device in two acceptable locations in two different limbs at each dosing visit. |
| Placebo Group C | PLACEBO_COMPARATOR | Participants will receive 1 ID injection of 1 mg/dose placebo followed by EP using the CELLECTRA™ 2000 device. |
| Placebo Group D | PLACEBO_COMPARATOR | Participants will receive 2 ID injections of 1 mg/dose placebo followed by EP using the CELLECTRA™ 2000 device in two acceptable locations in two different limbs at each dosing visit.. |
| Placebo Comparator Group A | PLACEBO_COMPARATOR | Participants will receive 1 ID injection of 1 mg/dose placebo followed by EP using the CELLECTRA® 2000 device |
| Placebo Comparator Group B | PLACEBO_COMPARATOR | Participants will receive 2 ID injections of 1 mg/dose placebo followed by EP using the CELLECTRA® 2000 device |
| Name | Type | Description |
|---|---|---|
| INO-4500 | DRUG | INO-4500 will be administered ID on Day 0 and Week 4. |
| CELLECTRA™ 2000 | DEVICE | EP using the CELLECTRA™ 2000 device will be administered following ID drug administration. |
| Placebo | DRUG | Placebo will be administered ID on Day 0 and Week 4. |
| CELLECTRA® 2000 | DEVICE | EP using the CELLECTRA® 2000 device will be administered following ID drug administration. |
Inclusion Criteria: * Judged to be healthy by the Investigator on the basis of medical history, physical examination and vital signs performed at Screening; * Negative tests for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody and Human Immunodeficiency Virus (HIV) antibody; * Screening el...
INO-4500 is an investigational drug being developed for the prevention of Lassa Fever, an infectious disease. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in healthy volunteers to assess its safety, tolerability, and immunogenicity.
INO-4500 is being developed by Inovio Pharmaceuticals, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol INO. The company is conducting clinical trials to evaluate the drug's potential as a preventive measure against Lassa Fever.
INO-4500 is in Phase 1 clinical development. It is an investigational drug and has not yet received approval from regulatory agencies. The Phase 1 trials have been completed, and the drug is not currently in active clinical trials, as per the latest available data.
INO-4500 has been studied in two completed Phase 1 clinical trials. The first trial, NCT03805984, enrolled 60 healthy volunteers in the United States. The second trial, NCT04093076, enrolled 220 healthy volunteers in Ghana. Both trials were randomized, double-blind, and placebo-controlled, focusing on safety, tolerability, and immunogenicity.
INO-4500 is a small molecule drug designed to target Lassa Fever. The specific molecular target or mechanism of action has not been disclosed in the available information. The drug is being evaluated for its ability to generate an immune response against the Lassa virus in healthy individuals.